In this multiple-dose to steady-state study , participants received once-daily subcutaneous administrations of either 0.4 ( cohort 1 ) or 0.6 units kg ( -1 ) ( cohort 2 ) Gla-300 for 8 days in one treatment period and 0.4 units kg ( -1 ) Gla-100 for 8 days in the other .